Drugs that Induce Bone Growth
This article was originally published in Start Up
Inspired by the commercializing of Lilly's osteoporosis drug, Forteo, start-ups are developing new classes of anabolic bone-forming agents around known and novel drug targets.
You may also be interested in...
University of Louisville spin-out Pradama is developing bone-targeting technology that it says will precisely deliver estrogen drugs to promote bone growth without the side effects of other estrogen receptor modulators. Preclinical tests on its lead product for osteoporosis will begin in the first quarter of 2009.
A discovery of the mechanism behind rare genetic condition sclerosteosis led to some new insights about bone growth. OsteoGeneX has now set out to discover small molecules that could inhibit the sclerostin pathway in a variety of potential applications including increasing bone growth in osteoporosis patients, spinal fusion and fracture repair.
Rotterdam-based Therosteon is developing therapeutics for bone diseases including osteoporosis, osteoarthritis, and bone metastasis using its OsteoBLAST drug discovery platform, developed by company founder and chief scientific officer, Hans van Leeuwen.